Martin Edelman, MD, Talks About Improving Outcomes in the Management of NSCLC
Martin Edelman, MD, Greenbaum Cancer Center, Baltimore, MD, says that organizations like NCCN and ASCO have guidelines for the management of non-small cell lung cancer (NSCLC). "I think that by utilizing these various clinical as well as biological markers, we can develop therapies that are tailored to the individual patient and have substantial evidence to support their use," said Dr Edelman.
This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.
Autophagy functions in numerous critical ways, including in quality control, cell remodeling, and energy production. Understanding the molecular pathways of autophagy can result in understanding and treating neurodegenerative disorders, metabolic disorders, and physiologic changes associated with aging.
Paul Wicks, PhD, vice president of innovation at PatientsLikeMe, discussed the benefits of using technology in multiple sclerosis research by patients, providers, researchers, and other decision-makers.
The Patient-Centered Outcomes Research Institute (PCORI) has announced the approval of 50 research funding awards, totaling $30 million over two years, through its Pilot Projects Program, which will address a broad range of questions about methods for engaging patients in the health research and dissemination process.
Current novel therapeutics for the prevention and treatment of bone loss in patients with inflammatory joint disease target cytokines and other inflammatory mediators. Mesenchymal stem cell therapy is a compelling new treatment currently being studied in clinical trials.
Bone erosion, a common side-effect of rheumatoid arthritis, can be prevented by using a combination of close patient monitoring and individualized therapeutic regimens that include agents to block cytokines, block osteoclasts, or target abnormal cellular reactions.